Clinical Trials Literature

Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial.

Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial.

Clinical Trials Literature
Publication date: Jul 08, 2026Post-acute sequelae of COVID-19 or post-COVID-19 condition (also known as long COVID) affects 1-5% of adults globally, most commonly with fatigue, and no evidence-based therapies are ... Read more
Investigation of barriers and facilitators to implementing a randomised controlled trial during health emergency using the PEARLES framework: insights from the coverage Africa trial on COVID-19 treatments in Burkina Faso.

Investigation of barriers and facilitators to implementing a randomised controlled trial during health emergency using the PEARLES framework: insights from the coverage Africa trial on COVID-19 treatments in Burkina Faso.

Clinical Trials Literature
Publication date: Jul 06, 2026Preparedness for emerging pathogens can be strengthened by leveraging lessons from COVID-19 therapeutic trials. The COVERAGE Africa trial (NCT04920838, ANRS033, 2021-22), one of the few COVID-19 ... Read more
Safety and immunogenicity of a COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase 1/2 clinical trial.

Safety and immunogenicity of a COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase 1/2 clinical trial.

Clinical Trials Literature
Publication date: Dec 01, 2026Based on viral evolution, increases in seasonal infections, and facilitation of delivery, an annual combination vaccine simultaneously targeting influenza and SARS-CoV-2 would benefit public health. The ... Read more